This multidistrict class action on behalf of purchasers of Coumadin, the brand-name warfarin sodium manufactured and marketed by DuPont Pharmaceutical Company. Plaintiffs alleged that the defendant engaged in anticompetitive conduct that wrongfully suppressed competition from generic warfarin sodium. The Court granted final approval to a $44.5 million settlement. See In re Warfarin Sodium Antitrust Litig., 212 F.R.D. 231 (D. Del. 2002).